PolyMedix, Inc. (OTC:PYMX) has announced that it will sell stock and warrants worth up to $21 million. Each sale unit, consisting of one share of PolyMedix common stock, and one warrant for five years to purchase .30 additional shares at $1.25 each, will cost $1. The sale will close on Monday. The company’s shares were down 35 cents in noon trading today, trading at 95 cents.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
A biotechnology company, PolyMedix, Inc. is focused on treating life threatening, serious, infectious diseases and acute cardiovascular disorders. The company treats with synthetic small molecule compounds, otherwise known as biomimetics designed to mimic large natural protein molecules. Using this drug technology, the company has developed defensin mimetic antibiotic, heparin antagonist, and other drug compounds for human therapeutic use.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
